Kite scores a land­mark win with promis­ing 6-month lym­phoma da­ta for lead CAR-T

Kite Phar­ma’s close­ly-watched lead CAR-T turned in pos­i­tive six-month re­sults for ag­gres­sive non-Hodgkin lym­phoma, hit­ting a key goal as the biotech rolls up to the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER